Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Core Insights - Instil Bio has entered into a definitive agreement to in-license ex-China development and commercialization rights for ImmuneOnco's bispecific antibody IMM2510 and next-generation anti-CTLA-4 antibody IMM27M [1][4] Group 1: Product Details - IMM2510 is a bispecific antibody that combines an anti-PD-L1 antibody with a VEGF receptor "trap," allowing it to bind multiple VEGF receptor ligands and potentially improve tumor penetration and efficacy [2] - IMM27M is designed to enhance ADCC activity and promote regulatory T cell depletion, aiming to improve efficacy and reduce toxicity compared to first-generation anti-CTLA-4 antibodies [3] Group 2: Clinical Development - IMM2510 has completed a dose-escalation clinical trial for advanced solid tumors, showing responses in patients with squamous non-small cell lung cancer who previously failed PD-1 inhibitors [2] - IMM27M has also completed a dose-escalation clinical trial and has entered combination studies with IMM2510 in China as of July 2024 [3] Group 3: Financial Terms - Under the agreement, Instil will pay an upfront fee and potential near-term payments totaling up to $50 million, along with additional milestone payments exceeding$2 billion and royalties on global ex-China sales [4]